How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

355 results for

Uric Acid Nephrolithiasis

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. CT-based Diagnosis of Visceral Obesity and Hepatic Steatosis is Associated with Low Urine pH. (PubMed)

CT-based Diagnosis of Visceral Obesity and Hepatic Steatosis is Associated with Low Urine pH. Uric acid nephrolithiasis is associated with an elevated visceral fat area in kidney stone formers. Hepatic steatosis has also been linked to visceral obesity and nephrolithiasis. We evaluated the association of noncontrast computerized tomography based diagnosis of visceral obesity and hepatic steatosis with 24-hour urine parameters and stone composition in kidney stone formers.A total of 98 kidney (...) ) and visceral fat area greater than 48% (OR 5.33) were associated with uric acid stones. Linear regression demonstrated that the percent of visceral fat area was associated with lower 24-hour urine pH (β-coefficient -0.438, p <0.0001).Noncontrast computerized tomography based diagnosis of visceral obesity is associated with low urine pH, high urinary sodium and uric acid stone formation. Hepatic steatosis is associated with low urine pH.Copyright © 2017 American Urological Association Education and Research

2017 Journal of Urology

102. Zurampic - lesinurad

SD standard deviation SE standard error SI International System of Units SMQ Standardised MedDRA Query SOC (MedDRA) system organ class sUA serum uric acid (also referred to as serum urate) SURI selective uric acid reabsorption inhibitor TEAE treatment-emergent adverse event UK United Kingdom ULT urate-lowering therapy URAT1 uric acid transporter 1 US United States uUA urinary uric acid vs versus XO xanthine oxidase XOI xanthine oxidase inhibitor Assessment report EMA/6459/2016 Page 5/128 1 (...) treatment of hyperuricaemia in combination with allopurinol or febuxostat in gout patients when additional therapy is warranted (i.e. not at target serum uric acid levels or with presence of tophus). Zurampic is indicated in adults. The legal basis for this application refers to: Article 8.3 of Directive 2001/83/EC - complete and independent application. The applicant indicated that lesinurad was considered to be a new active substance. The application submitted is composed of administrative information

2016 European Medicines Agency - EPARs

103. (SWL) Versus (ODT) Versus Combined SWL And ODT For Radiolucent Stone

-dihydroxyadenine calculi. The main etiologic factors for the development of uric acid nephrolithiasis are low urinary pH, hyperuricosuria, and low urinary volume. Practically, all of those who form uric acid stones have persistently low urinary pH, and most excrete normal amounts of uric acid. This suggests the potential importance of urinary pH manipulation in dissolving UA stones. Dissolution therapy for UA calculi is based on hydration and raising the urinary pH. European guidelines recommended that urine (...) and dissolution therapy Not Applicable Detailed Description: Urolithiasis is a common morbidity worldwide, affecting 10% to 15% of the population in Europe and North America. A higher prevalence of stone disease is found in hot or dry areas, including 20% to 25% in the Middle East. Radiolucent stones are mostly uric acid (UA) calculi, which varies geographically with worldwide incidence ranges from 5 to 40% and about 7- 10 percent of all calculi. Other rare radiolucent stones include xanthine and 2,8

2017 Clinical Trials

104. This Study Tests the Effect of Certain Medicines on the Transport of Other Medicines in the Body of Healthy Men

disorders (e.g. sinu-atrial blocks of II° or III°) Myopathy Hereditary galactose or fructose intolerance, lactase deficiency, or glucose-galactose malabsorption History of nephrolithiasis Gout or clinically relevant elevation of uric acid Creatinine clearance (according to CKD EPI formula) is lower than 80 ml/min Further exclusion criteria apply Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research (...) Mechanisms of Pharmacological Action Lipid Regulating Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Enzyme Inhibitors Diuretics Natriuretic Agents Sodium Potassium Chloride Symporter Inhibitors Membrane Transport Modulators Antibiotics, Antitubercular Antitubercular Agents Anti-Bacterial Agents Anti-Infective Agents Leprostatic Agents Nucleic Acid Synthesis Inhibitors Cytochrome P-450 CYP2B6 Inducers Cytochrome P-450 Enzyme Inducers Cytochrome P-450 CYP2C8 Inducers

2017 Clinical Trials

105. Phase 2 Dose-finding IMU-838 for Ulcerative Colitis

for fluctuating liver function tests during this trial Renal impairment i.e. calculated creatinine clearance ≤60 mL/min Serum uric acid levels at Screening >1.2 x ULN (for women >6.8 mg/dL, for men >8.4 mg/dL) History or clinical diagnosis of gout Known or suspected Gilbert syndrome Indirect (unconjugated) bilirubin ≥1.2 x ULN at Screening (i.e. ≥ 1.1 mg/dL) Concurrent malignancy or prior malignancy within the previous 10 years except for the following: adequately-treated non-melanoma skin cancer (...) and ustekinumab within 8 weeks before first randomization Use of the DHODH inhibitors leflunomide or teriflunomide within 6 months before first randomization Any use of natalizumab (Tysabri™) within 12 months before first randomization Use of the following concomitant medications is prohibited at Screening and throughout the duration of the trial: any medication known to significantly increase urinary elimination of uric acid, in particular lesinurad (Zurampic™) as well as uricosuric drugs such as probenecid

2017 Clinical Trials

106. Association Study of Reported Significant Loci at 5q35.3, 7p14.3, 13q14.1 and 16p12.3 with Urolithiasis in Chinese Han Ethnicity (PubMed)

with increased level of serum magnesium. The C allele of rs1000597 was associated with higher levels of serum creatinine, uric acid, calcium and lower urine pH level. The T allele of rs4142110 was correlated with higher levels of serum magnesium, phosphorus, and lower AKP level. The G alleles of rs4293393 was associated with higher serum CO2 level. The risk alleles of these SNPs were proved to be associated with the electrolytes metabolism that may result in the formation of urolithiasis. (...) Association Study of Reported Significant Loci at 5q35.3, 7p14.3, 13q14.1 and 16p12.3 with Urolithiasis in Chinese Han Ethnicity In this study, we aimed to validate the association of 8 reported significant loci at 5q35.3, 7p14.3, 13q14.1 and 16p12.3 with urolithiasis in Chinese Han population. We performed case-control association analysis using 624 patients with nephrolithiasis and 1008 control subjects. We selected single-nucleotide polymorphism (SNPs) including rs12654812 and rs11746443

Full Text available with Trip Pro

2017 Scientific reports

107. Bilateral hydronephrosis due to obstructive ureteral stone associated with norovirus gastroenteritis (PubMed)

Bilateral hydronephrosis due to obstructive ureteral stone associated with norovirus gastroenteritis Recently, cases of urinary tract calculi causing hydronephrosis and postrenal renal failure associated with viral gastroenteritis were documented, yet few were related to norovirus. During norovirus gastroenteritis, observation of oliguria, aciduria, low FENa value, and elevation of blood or urinary uric acid level may necessitate clinical workout for nephrolithiasis.

Full Text available with Trip Pro

2017 Clinical Case Reports

108. Preventive Kidney Stones: Continue Medical Education (PubMed)

abdominal film and renal sonography, a noncontrast helical computed tomography scan of the abdomen is the diagnostic procedure of choice for detection of small and radiolucent kidney stones with sensitivity and specificity of nearly 100%. Stones smaller than 5 mm in diameter often pass the urinary tract system and rarely require surgical interventions. The main risk factors for stone formation are low urine output, high urinary concentrations of calcium, oxalate, phosphate, and uric acid compounded (...) Preventive Kidney Stones: Continue Medical Education Nephrolithiasis is a common health problem across the globe with a prevalence of 15%-20%. Idiopathic hypercalciuria is the most common cause of nephrolithiasis, and calcium oxalate stones are the most common type of stones in idiopathic hypercalciuric patients. Calcium phosphate stones are frequently associated with other diseases such as renal tubular acidosis type 1, urinary tract infections, and hyperparathyroidism. Compared with flat

Full Text available with Trip Pro

2017 International journal of preventive medicine

110. 2012 KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD

pressure 490 th percentile ando95 th percentile), following the age-based Recommended Daily Intake. (1C) We recommendsupplemental freewater and sodiumsupplementsforchildrenwith CKD and polyuria to avoid chronic intravascular depletion and to promote optimal growth. (1C) Hyperuricemia 3.1.20: There is insuf?cient evidence to support or refute the use of agents to lower serum uric acid concentrations in people with CKD and either symptomatic or asymptomatic hyperuricemia in order to delay (...) antihypertensive agents; K persistent abnormalities of serum potassium; K recurrent or extensive nephrolithiasis; K hereditary kidney disease. 5.1.2: We recommend timely referral for planning renal replacement therapy (RRT) in people with progressive CKD in whom the risk of kidney failure within 1 year is 10–20% or higher w , as determined by validated risk prediction tools. (1B) *If this is a stable isolated ?nding, formal referral (i.e., formal consultation and ongoing care management) may not be necessary

2012 National Kidney Foundation

111. Health Supervision in the Management of Children and Adolescents With IBD: NASPGHAN Recommendations

of urine creatinine, electrolytes, calcium, magnesium, uric acid, citrate, oxalate, volume, and pH should be obtained. Bone Health in Children With IBD Recent data underscore the need for physicians caring for children with IBD to pay particular attention to assessing and ensuring adequate vitamin D and calcium intake by their patients. Significant deficits in bone mass have been observed in 10% to 40% of children presenting with IBD, and these deficits appear to be more pronounced in patients with CD (...) involving the small bowel, especially those with extensive disease or resections involving the terminal ileum, should have periodic assessment of serum vitamin B 12 and folate levels. Patients with CD and either significant small bowel involvement or a history of small bowel resection are also at increased risk for the development of zinc deficiency (44). Similarly, patients with CD who have undergone terminal ileal resection are at increased risk for impaired absorption of bile acids. These unabsorbed

2012 North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition

112. Obstructive Uropathy as an Initial Presentation of Primary Myelofibrosis: Case Report and Review of Literature (PubMed)

Obstructive Uropathy as an Initial Presentation of Primary Myelofibrosis: Case Report and Review of Literature Primary myelofibrosis (PMF) is a rare hematological disorder associated with progressive cytopenia and extra-medullary hematopoiesis. Acute kidney injury in this disease has been reported from diverse etiologies such as renal and peri-renal extramedullary hematopoiesis and tumor lysis syndrome. We report a patient who presented with obstructive uropathy from uric acid stones who (...) was incidentally diagnosed with PMF during workup for persistent thrombocytosis and leukocytosis. Marrow histopathology was unique in presenting features of early PMF despite clinical picture mimicking essential thrombocythemia. Despite a common background of hyperuricemia in myeloproliferative neoplasms, AKI resulting from urate nephrolithiasis has seldom been reported in PMF. Published data on this association and clinical management is reviewed briefly.

Full Text available with Trip Pro

2016 Indian Journal of Hematology & Blood Transfusion

113. Understanding the Urine Electrolyte Profile of the Individual Renal Unit

, oxalate, potassium, magnesium, phosphate, uric acid, and urate. When an abnormality is detected on a 24-hour urine collection the assumption is that this is due to a global metabolic defect present in both kidneys. However, this may not be the case. It is possible there could be a relative imbalance with both kidneys having a defect, but to different degrees (or different defects in one or multiple electrolytes). It is also possible that one kidney has a dominant defect, but the contralateral kidney (...) in the concentrations of urine electrolytes, such as calcium. Condition or disease Intervention/treatment Kidney Calculi Nephrolithiasis Urolithiasis Procedure: Ureteral catheterization Detailed Description: Nephrolithiasis is common within the general population. Although the majority of patients with a symptomatic stone event will not require surgical intervention, the rate of recurrence is high. Therefore, reducing this rate of recurrence is important. Traditionally, this has been achieved with a combination

2016 Clinical Trials

114. Study to Evaluate the Efficacy and Safety of DS-1971a for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)

disorders such as bipolar disorder, schizophrenia, or major depression. Abnormal liver function (aspartate aminotransferase/alanine aminotransferase (AST/ALT) > 2.5 × upper limit of normal (ULN), bilirubin > 1.5 ULN). Subjects with history of gout, and/or urate nephrolithiasis, and/or with abnormally low serum uric acid (below the lowest laboratory reference range both in men and women) at baseline. Other sources of pain that may confound assessment or self-evaluation of DPNP such as disseminated

2016 Clinical Trials

115. Influence of Hypocaloric Diet on Urinary Lithogenic Factors of Obese Patients With Kidney Stones

and requested total serum calcium, phosphate, sodium, potassium, urea, creatinine, uric acid, and PTH, pH venous blood, urine tests type I, culture of urine and urine tests of calcium, oxalate, phosphate, sodium, potassium, citrate, magnesium, creatinine, uric acid, cystine and computed tomography for evaluation of urinary calculus. In the second evaluation, 30 days after, anthropometric measures will be repeated, bioimpedance and nutritional assessment will be made with recommendation of daily ingestion (...) of 2500 ml of water and low-calorie diet of 16 Kcal/kg bw/day and requested total serum calcium, phosphate, sodium, potassium, urea, creatinine, uric acid, and PTH, pH venous blood, urine tests type I, culture of urine and urine tests of calcium, oxalate, phosphate, sodium, potassium, citrate, magnesium, creatinine, uric acid, cystine. Patients will be monitored monthly for 3 months with anthropometric measurements, bioimpedance and strengthening of nutritional recommendations. By the end of the third

2016 Clinical Trials

116. Bacterial Analysis of Kidney Stones Removed by Percutaneous Nephrolithotomy

characterized. Previous studies have found bacteria present in stones of patients without active infection and with negative pre-operative urine tests. There are various compositions of kidney stones, including calcium oxalate, calcium phosphate, struvite and uric acid, with calcium oxalate being the most common. It is well known that struvite stones are associated with active infection, however the role of bacteria in the formation of other types of kidney stones, including calcium oxalate, is not well (...) First Posted: April 15, 2016 Last Update Posted: May 2, 2018 Last Verified: November 2016 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Keywords provided by Dirk Lange, University of British Columbia: Kidney stones Renal Calculi Additional relevant MeSH terms: Layout table for MeSH terms Kidney Calculi Nephrolithiasis Urolithiasis Kidney Diseases Urologic Diseases Urinary Calculi Calculi Pathological Conditions, Anatomical

2016 Clinical Trials

117. Uromodulin in kidney health and disease. (PubMed)

estimated glomerular filtration rate (eGFR) and kidney size, possibly indicating greater kidney functional reserve. Greater uromodulin excretion is associated with markers of volume overload such as fractional excretion of uric acid, sodium and chloride, indicating a possible role in salt and water retention. Recent evidence also suggests that higher uromodulin levels are associated with lower risk of eGFR decline, death and possibly a lower risk of acute kidney injury. Higher levels of uromodulin (...) Uromodulin in kidney health and disease. Although uromodulin or Tamm-Horsfall protein was discovered over 60 years ago, its functional role in humans remains unclear. This review highlights new studies elucidating the clinical correlates of uromodulin, its association with kidney function decline, nephrolithiasis and urinary host defense.Uromodulin is evolutionarily conserved and has multiple functional roles. In large population studies, higher levels of uromodulin are associated with higher

2016 Current Opinion in Nephrology and Hypertension

118. Do Overweight and Obese Pediatric Stone Formers Have Differences in Metabolic Abnormalities Compared with Normal Weight Stone Formers? (PubMed)

%). Univariable and multivariable analyses revealed that overweight and obese children were more likely to have low urinary volume and elevated uric acid compared to normal-weight children.Although there is a link between stone formation and BMI in adults, no definitive conclusions have been proven in the pediatric literature. Our study indicates that stone-forming children who are overweight or obese have low urinary volume and elevated uric acid compared to normal-weight stone-forming children.Copyright © (...) Do Overweight and Obese Pediatric Stone Formers Have Differences in Metabolic Abnormalities Compared with Normal Weight Stone Formers? To determine if 24-hour urinary parameters in children with nephrolithiasis across 4 institutions were influenced by body mass index (BMI).The 24-hour urinary parameters obtained from children with nephrolithiasis between 2000 and 2013 were stratified by BMI percentile ≥85th and <85th (overweight and obese patients vs healthy weight, respectively). A total

2016 Urology

119. A Novel Homozygous SLC2A9 Mutation Associated with Renal-Induced Hypouricemia. (PubMed)

A Novel Homozygous SLC2A9 Mutation Associated with Renal-Induced Hypouricemia. Hereditary renal hypouricemia (RHUC) is a genetically heterogenous disorder characterized by defective uric acid (UA) reabsorption resulting in hypouricemia and increased fractional excretion of UA; acute kidney injury (AKI) and nephrolithiasis are recognized complications. Type 1 (RHUC1) is caused by mutations in the SLC22A12 gene, whereas RHUC2 is caused by mutations in the SLC2A9 gene. Patient ethnicity is diverse

Full Text available with Trip Pro

2016 American journal of nephrology

120. The Effect of Vitamin D Repletion on Kidney Stone Risk

Criteria: Known uric acid, cystine, or struvite stone disease Hypercalcemia (serum calcium >10.4 mg/dl within the past 12 months) Gross hematuria within the past 6 months Acute stone event within the past 1 month Recent stone intervention within the past 1 month Suspected or known secondary causes of hypercalciuria such as primary hyperparathyroidism, sarcoidosis, hyperthyroidism, or malignancy (except non-melanoma skin cancer) Addition or dose change of medicines potentially affecting urinary calcium (...) followed at Miriam Hospital Kidney Stone Clinic with history of nephrolithiasis, urinary calcium excretion between 150 and 400 mg/day, and 25-vitamin D deficiency/insufficiency (defined as serum level ≤ 30ng/ml). The intervention is oral ergocalciferol 50,000 IU per week for 12 weeks (repletion course). After that, the same repletion course will be repeated if serum 25-vitamin D remains ≤ 30ng/ml or drops to ≤ 30ng/ml anytime during the study. Otherwise, a maintenance dose of cholecalciferol 1,000 IU

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>